Standard BioTools Reports First Quarter 2026 Financial Results

May 6, 2026 - 03:41

BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. reported its financial results for the first quarter of 2026 on Tuesday, posting revenue of $21.1 million for the period ending March 31. The company highlighted a significant reduction in operating losses, which fell by 54 percent compared to the same quarter last year. Adjusted EBITDA also saw a 78 percent improvement year-over-year, a move management says puts the firm on track to reach positive adjusted EBITDA by the end of 2026.

The company reported a strong cash position, holding $524 million in cash and investments as of March 31. This figure does not include a $25 million earnout payment received after the quarter closed. Standard BioTools attributed the improved financial performance to ongoing cost discipline and operational efficiencies implemented over the past year.

While the company did not provide specific forward guidance in the release, executives noted that the first quarter results reflect steady execution of their strategic plan. The focus remains on driving revenue growth while maintaining control over expenses. Standard BioTools continues to operate in the life sciences tools space, providing instruments and consumables for proteomics and genomics research. The full financial details were made available in the company's filing with the Securities and Exchange Commission.